111 related articles for article (PubMed ID: 33405993)
1. Safety, pharmacokinetics and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist in healthy individuals.
Hu Y; Zhang H; Wu M; Liu J; Li X; Zhu X; Li C; Chen H; Liu C; Niu J; Ding Y
Expert Opin Investig Drugs; 2021 Mar; 30(3):263-269. PubMed ID: 33405993
[TBL] [Abstract][Full Text] [Related]
2. A Single and Multiple Ascending Dose Study of Toll-Like Receptor 7 Agonist (RO7020531) in Chinese Healthy Volunteers.
Luk A; Jiang Q; Glavini K; Triyatni M; Zhao N; Racek T; Zhu Y; Grippo JF
Clin Transl Sci; 2020 Sep; 13(5):985-993. PubMed ID: 32268000
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist.
Lopatin U; Wolfgang G; Tumas D; Frey CR; Ohmstede C; Hesselgesser J; Kearney B; Moorehead L; Subramanian GM; McHutchison JG
Antivir Ther; 2013; 18(3):409-18. PubMed ID: 23416308
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers.
Grippo JF; Folitar I; Passe S; Jiang Q; Rodriguez I; Fettner SH; Calleja E
Clin Transl Sci; 2021 Jul; 14(4):1524-1534. PubMed ID: 33742764
[TBL] [Abstract][Full Text] [Related]
5. JNJ-64794964 (AL-034/TQ-A3334), a TLR7 agonist, induces sustained anti-HBV activity in AAV/HBV mice via non-cytolytic mechanisms.
Herschke F; Li C; Zhu R; Han Q; Wu Q; Lu Q; Barale-Thomas E; De Jonghe S; Lin TI; De Creus A
Antiviral Res; 2021 Dec; 196():105196. PubMed ID: 34718044
[TBL] [Abstract][Full Text] [Related]
6. Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjects.
Reyes M; Lutz JD; Lau AH; Gaggar A; Grant EP; Joshi A; Mackman RL; Ling J; Tan SK; Ayithan N; Daffis S; Woo J; Wu P; Lam T; Fletcher SP; Kottilil S; Poonia B; Gane EJ; Mathias A; German P
Antivir Ther; 2020; 25(3):171-180. PubMed ID: 32667286
[TBL] [Abstract][Full Text] [Related]
7. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.
Gane EJ; Lim YS; Gordon SC; Visvanathan K; Sicard E; Fedorak RN; Roberts S; Massetto B; Ye Z; Pflanz S; Garrison KL; Gaggar A; Mani Subramanian G; McHutchison JG; Kottilil S; Freilich B; Coffin CS; Cheng W; Kim YJ
J Hepatol; 2015 Aug; 63(2):320-8. PubMed ID: 25733157
[TBL] [Abstract][Full Text] [Related]
8. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.
Janssen HLA; Brunetto MR; Kim YJ; Ferrari C; Massetto B; Nguyen AH; Joshi A; Woo J; Lau AH; Gaggar A; Subramanian GM; Yoshida EM; Ahn SH; Tsai NCS; Fung S; Gane EJ
J Hepatol; 2018 Mar; 68(3):431-440. PubMed ID: 29104121
[TBL] [Abstract][Full Text] [Related]
9. A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer.
Zuo X; Cheng Q; Wang Z; Liu J; Lu W; Wu G; Zhu S; Liu X; Lv T; Song Y
Int Immunopharmacol; 2024 Jun; 137():112478. PubMed ID: 38901243
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8.
Port A; Shaw JV; Klopp-Schulze L; Bytyqi A; Vetter C; Hussey E; Mammasse N; Ona V; Bachmann A; Strugala D; Reh C; Goteti K
Pharmacol Res Perspect; 2021 Oct; 9(5):e00842. PubMed ID: 34414672
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C.
Lawitz E; Gruener D; Marbury T; Hill J; Webster L; Hassman D; Nguyen AH; Pflanz S; Mogalian E; Gaggar A; Massetto B; Subramanian GM; McHutchison JG; Jacobson IM; Freilich B; Rodriguez-Torres M
Antivir Ther; 2015; 20(7):699-708. PubMed ID: 25105516
[TBL] [Abstract][Full Text] [Related]
12. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U
Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752
[TBL] [Abstract][Full Text] [Related]
13. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
14. First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MHV370, a Dual Inhibitor of Toll-Like Receptors 7 and 8, in Healthy Adults.
Shisha T; Posch MG; Lehmann J; Feifel R; Junt T; Hawtin S; Schuemann J; Avrameas A; Danekula R; Misiolek P; Siegel R; Gergely P
Eur J Drug Metab Pharmacokinet; 2023 Sep; 48(5):553-566. PubMed ID: 37532923
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.
Timmers M; Ravenstijn P; Xi L; Triana-Baltzer G; Furey M; Van Hemelryck S; Biewenga J; Ceusters M; Bhattacharya A; van den Boer M; van Nueten L; de Boer P
J Psychopharmacol; 2018 Dec; 32(12):1341-1350. PubMed ID: 30260294
[TBL] [Abstract][Full Text] [Related]
16. First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.
Wang L; Lu J; Zhou S; Zhao Y; Xie L; Zhou C; Chen J; Ding S; Xie D; Ding J; Yu Q; Shen H; Hao G; Shao F
Clin Drug Investig; 2021 Nov; 41(11):999-1010. PubMed ID: 34655432
[TBL] [Abstract][Full Text] [Related]
17. Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV.
Bergmann JF; de Bruijne J; Hotho DM; de Knegt RJ; Boonstra A; Weegink CJ; van Vliet AA; van de Wetering J; Fletcher SP; Bauman LA; Rahimy M; Appleman JR; Freddo JL; Janssen HL; Reesink HW
Aliment Pharmacol Ther; 2011 Aug; 34(4):443-53. PubMed ID: 21707679
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of MT-1207, a novel multitarget blocker of α1 receptor, 5-HT2A receptor, and calcium channel, in healthy subjects.
Zhang H; Wu M; Hu Y; Li C; Zheng W; Liu J; Li X; Zhu X; Ding Y
Expert Opin Investig Drugs; 2021 Mar; 30(3):271-278. PubMed ID: 33560891
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects.
Wang S; Chen G; Merlo Pich E; Affinito J; Cwik M; Faessel H
Br J Clin Pharmacol; 2021 Nov; 87(11):4354-4365. PubMed ID: 33837574
[TBL] [Abstract][Full Text] [Related]
20. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
Fowler A; Koenen R; Hilbert J; Blatchford J; Kappeler D; Benediktus E; Wood C; Gupta A
J Clin Pharmacol; 2017 Nov; 57(11):1444-1453. PubMed ID: 28609567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
